Sandoz Group AG (LON:0SAN)
London
· Delayed Price · Currency is GBP · Price in CHF | Market Cap | 28.44B |
| Revenue (ttm) | 8.29B |
| Net Income (ttm) | 679.10M |
| Shares Out | n/a |
| EPS (ttm) | 1.55 |
| PE Ratio | 41.88 |
| Forward PE | 21.93 |
| Dividend | 0.55 (0.83%) |
| Ex-Dividend Date | Apr 17, 2025 |
| Volume | 102,732 |
| Average Volume | 218,780 |
| Open | 69.38 |
| Previous Close | 71.59 |
| Day's Range | 67.58 - 69.66 |
| 52-Week Range | 26.99 - 72.69 |
| Beta | 0.26 |
| RSI | 63.23 |
| Earnings Date | Feb 25, 2026 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
News
Sandoz Group AG (SDZNY) Full Year 2025 Earnings Call Highlights: Strong Biosimilar Growth and ...
Sandoz Group AG (SDZNY) Full Year 2025 Earnings Call Highlights: Strong Biosimilar Growth and Strategic Acquisitions Propel Performance
Full Year 2025 Sandoz Group AG Earnings Call Transcript
Full Year 2025 Sandoz Group AG Earnings Call Transcript
Sandoz Group AG 2025 Q4 - Results - Earnings Call Presentation
2026-02-25. The following slide deck was published by Sandoz Group AG in conjunction with their 2025 Q4 earnings call.
Sandoz Group AG Non-GAAP EPS of $3.64 beats by $0.38, revenue of $11.1B beats by $20M
Sandoz Shares Jump on Improved Guidance
Sandoz Group AG (SDZNY) Q4 2025 Earnings Call Transcript
Sandoz CEO: Europe must unite to protect local drug makers
Richard Saynor, CEO of pharmaceuticals business, Sandoz, discusses the company's development of GLP-1 medication, international drug pricing, and the ongoing impact of tariffs on the firm.
Sandoz wins FDA nod to expand Enzeevu label to multiple retinal indications
FDA expands Enzeevu label for multiple retinal diseases, boosting Sandoz’ biosimilar ophthalmology push.